Abstract: When a tumor or scar tissue narrows the trachea, every breath becomes a struggle. An airway stent—a small mesh or silicone tube placed through a bronchoscope—can reopen that passage in minutes, buying patients time for definitive treatment and immediate relief from suffocation. The global airway stent market is projected to reach USD 0.17 billion by 2030, growing at a 6.0% CAGR. The top 10 manufacturers held approximately 76.0% of revenue in 2023, a concentration that reflects both the procedure’s technical demands and the dominance of a few established device platforms. This analysis examines why lung stents are becoming a standard tool in interventional pulmonology, and what clinicians and procurement teams must weigh before building a stent program.

What Is an Airway Stent and Why Does It Matter?
During breathing, air passes through the bronchus into the lungs. Narrowing of the trachea can cause obstructive pneumonia, atelectasis, and difficulty breathing. Patients experience shortness of breath, wheezing, and coughing; severe cases can progress to respiratory failure and life-threatening conditions.

Tracheal stent placement is one of the primary methods for treating airway stenosis. It rapidly relieves breathing difficulties and improves clinical symptoms. Over the past two decades, advances in material science and the widespread adoption of flexible bronchoscopy have made airway stent utilization more prevalent, creating opportunities for further treatment and improving patient quality of life.

The clinical logic is straightforward: a stent does not cure the underlying disease. It restores airflow, creating a therapeutic window. Recent evidence reinforces this. A 2026 study of X-ray-guided Y-shaped covered self-expanding metallic stents in 22 patients with malignant central airway stenosis involving the carina reported a 100% technical success rate and 86.4% clinical success. Airway stenosis grade dropped from 4.09 to 1.14, and room-air oxygen saturation rose from 81.79% to 94.00% . Those numbers translate into patients who can breathe, speak, and leave the hospital—sometimes for months.

Market Size and Competitive Landscape
According to QYResearch’s Global Airway Stents (Lung Stents) Market Report 2024–2030, the global airway stent market is projected to reach USD 0.17 billion by 2030, at a 6.0% CAGR. Key manufacturers include Boston Scientific, Merit Medical Systems, Taewoong Medical, Bess Group, Stening, Cook Group, ELLA-CS, Micro-Tech, SEWOON MEDICAL, and Fuji Systems. In 2023, the global top 10 players held approximately 76.0% of revenue—a concentrated structure reflecting the capital intensity of device development, the importance of bronchoscopy suite integration, and brand loyalty built through clinical training programs.

Product segmentation reveals where volume sits. Silicone stents are the largest segment at 36.3% share, favored for benign disease and removable applications because they can be repositioned and extracted with relative ease. Metal stents, particularly nitinol-based self-expanding designs, dominate malignant indications where radial strength and low-profile delivery are critical. By application, adults account for 72.1% of demand, reflecting the epidemiology of lung cancer, COPD, and post-intubation stenosis.

The innovation frontier is moving toward reducing repeat interventions. In June 2026, Peytant Solutions announced the first-in-human implantation of its AMStent, the first airway stent covered with a human-sourced amniotic membrane designed to reduce granulation tissue formation . Separately, VisionAir Solutions received FDA 510(k) clearance in May 2026 for its Enhanced Stock Stent, a silicone Y-stent geometrically derived from population models of healthy airway anatomy—an off-the-shelf alternative to patient-specific devices . These developments signal that differentiation is shifting from “does the stent stay open” to “how long before the patient needs another procedure.”

Market Driving Factors
Increasing Prevalence of Respiratory Disorders
The rising prevalence of chronic obstructive pulmonary disease (COPD), lung cancer, and other respiratory conditions has significantly increased demand for airway stents. These conditions often lead to airway obstruction, making stent placement an essential option for improving airflow and patient quality of life. India alone recorded 37.8 million COPD cases, underscoring the scale of unmet need in fast-growing Asia-Pacific markets .

Advancements in Material Science and Medical Technology
Continued advancements in biocompatible metals and polymers have produced safer, more effective airway stents. Nitinol’s shape-memory properties allow low-profile delivery through a bronchoscope followed by self-expansion at body temperature. Hybrid designs pairing a metallic frame with a silicone or polyurethane covering reduce tumor ingrowth and granulation tissue formation. These innovations improve durability, flexibility, and biocompatibility, expanding clinical use.

Rising Geriatric Population
As the global population ages, the incidence of age-related respiratory diseases increases, driving demand for lung stents. Elderly patients often experience airway stenosis due to age-related changes or prolonged intubation, making stent placement a key solution for restoring respiratory function.

Increased Awareness of Minimally Invasive Procedures
Growing awareness of minimally invasive procedure benefits has shifted patient and provider preferences toward airway stent placement as an alternative to traditional surgery. The procedure is performed through rigid or flexible bronchoscopy, typically without open incisions, reducing recovery time and hospital stay. High-frequency jet ventilation using silicone catheters achieved 84% procedural success in 2024 with median operating times of 35 minutes and no postoperative complications, strengthening the clinical case for bronchoscopic stenting over open surgery .

Improved Patient Quality of Life
Airway stents significantly improve quality of life for patients with respiratory difficulties by relieving obstruction and enabling better airflow. This benefit drives both patient demand and physician recommendations. For palliative care patients, the ability to breathe comfortably without mechanical ventilation can mean the difference between dying in an ICU and spending final weeks at home.

Market Restraints
Risk of Complications
While airway stents offer significant benefits, their use is associated with potential complications including infection, stent migration, mucosal damage, and granulation tissue formation. These complications can hinder widespread adoption and may limit use in certain patients. The 2026 Y-stent study reported complications requiring intervention in 27.3% of patients, including secretion retention (18.2%) and restenosis due to granulation tissue hyperplasia (13.6%) . These figures underscore that stenting is a management strategy, not a cure, and that follow-up bronchoscopy is part of the cost of care.

High Cost of Treatment
The cost of airway stents, especially advanced stents made from high-end materials, can be prohibitively expensive. This limits access in low-income regions or for patients without sufficient healthcare coverage. The procedure itself—bronchoscopy suite time, anesthesia, physician expertise—adds substantially to the device cost. Recent tariff adjustments in 2025 have further increased the cost of raw materials, metal alloys, silicone components, and precision-manufactured expandable stents sourced across international supply chains, leading to higher production and procurement expenses .

Limited Long-Term Effectiveness
Over time, airway stents may lose effectiveness due to migration, mucosal irritation, or occlusion. This necessitates additional procedures or stent replacement, burdening patients and providers. Silicone stents are easier to remove but more prone to migration; metal stents resist migration but are difficult to extract once embedded. The clinical trade-off between durability and retrievability remains unresolved for benign disease.

Technical Challenges in Stent Placement
Stent placement is technically challenging, requiring skilled professionals to ensure correct positioning and avoid complications. Improper placement can lead to ineffective treatment and further complications. The global shortage of trained interventional pulmonologists capable of performing rigid bronchoscopy and complex stent placement constrains procedural volume growth even where devices are available.

An Overlooked Observation: Reimbursement Is the Hidden Gatekeeper
Device performance and clinical evidence matter, but in many health systems the adoption of airway stents is determined by payment codes. In China, a significant policy shift is underway. The National Healthcare Security Administration’s DRG/DIP 3.0 grouping scheme, released in 2026, creates a dedicated “complex respiratory intervention” category that explicitly includes airway stent placement . Previously, complex stent placement and routine bronchoscopy often fell into the same payment bucket, discouraging hospitals from offering advanced interventions. The new grouping carries a substantially higher weight, aligning reimbursement with resource consumption.

The implication for device makers is direct: market growth in price-sensitive systems depends not only on clinical superiority but on whether hospitals can get paid for the procedure. In markets where stent placement remains bundled with diagnostic bronchoscopy, adoption will lag regardless of device innovation.

Outlook
The airway stent market will grow steadily, driven by demographic and epidemiological fundamentals that show no sign of reversing: aging populations, persistent lung cancer burden, and the expansion of interventional pulmonology infrastructure in emerging economies. The 76.0% top-10 concentration means the competitive set is stable, but the innovation frontier is active—amniotic membrane coverings, population-modeled off-the-shelf Y-stents, and bioresorbable polymers are all moving toward clinical adoption. Bioresorbable polymers are the fastest-growing material segment, with a 9.07% CAGR through 2031, as clinicians prize temporary support without the burden of removal surgery .

For clinicians and procurement teams, the evaluation criteria extend beyond device specifications. Stent selection should account for indication (malignant vs. benign), removability requirements, local bronchoscopy expertise, and—critically—reimbursement pathways. The cheapest stent per unit may prove the most expensive per patient if it requires earlier replacement. The most advanced stent may go unused if the hospital cannot bill for its placement.

The device is small. The consequences of getting the choice wrong are not.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp